These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12201674

  • 41. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
    Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):373-7. PubMed ID: 8195036
    [Abstract] [Full Text] [Related]

  • 42. Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells.
    Masunaga S, Ono K, Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S, Nagasawa H, Uto Y.
    Int J Hyperthermia; 1999 May 15; 15(1):7-16. PubMed ID: 10193753
    [Abstract] [Full Text] [Related]

  • 43. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 44. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
    Adam M, Ottenjann S, Künzel G, Busch R, Erhardt W, Nieder C, Molls M.
    Strahlenther Onkol; 2006 Apr 15; 182(4):231-9. PubMed ID: 16622625
    [Abstract] [Full Text] [Related]

  • 45. Bioreductive drugs: from concept to clinic.
    McKeown SR, Cowen RL, Williams KJ.
    Clin Oncol (R Coll Radiol); 2007 Aug 15; 19(6):427-42. PubMed ID: 17482438
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 53. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
    Chinje EC, Patterson AV, Saunders MP, Lockyer SD, Harris AL, Stratford IJ.
    Br J Cancer; 1999 Dec 15; 81(7):1127-33. PubMed ID: 10584872
    [Abstract] [Full Text] [Related]

  • 54. Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice.
    Minchinton AI, Tonn DA, Sutherland DP, Kyle AH.
    Radiat Res; 2002 Jul 15; 158(1):94-100. PubMed ID: 12071808
    [Abstract] [Full Text] [Related]

  • 55. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
    Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR.
    Int J Radiat Oncol Biol Phys; 1998 Oct 01; 42(3):641-9. PubMed ID: 9806526
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.